Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) released its earnings results on Friday. The company reported ($0.01) EPS for the quarter, Zacks reports.
Guided Therapeutics Price Performance
GTHP remained flat at $0.20 during trading on Friday. The stock has a market capitalization of $19.31 million, a P/E ratio of -5.00 and a beta of 0.79. Guided Therapeutics has a fifty-two week low of $0.09 and a fifty-two week high of $0.54. The business has a 50 day moving average of $0.23 and a 200-day moving average of $0.30.
About Guided Therapeutics
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Read More
- Five stocks we like better than Guided Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
